Vioneo moves project to China; GSK to buy Rapt Therapeutics for $2.2 billion

The Chemistry of Now: Trends Shaping the Future of Industry From melting icy sidewalks to the complex world of pharmaceutical acquisitions, chemistry is the often-unseen force driving innovation and adaptation. Recent events – a harsh winter storm, major business deals, and emerging technologies – offer a glimpse into the trends poised to reshape the chemical … Read more

Eli Lilly Data Demand Sparks Hospital Backlash & 340B Fight

The 340B Program Under Fire: A Looming Data War Between Pharma and Hospitals The recent clash between Eli Lilly and the American Hospital Association (AHA) isn’t just a single dispute; it’s a harbinger of a much larger trend reshaping the pharmaceutical landscape. Lilly’s demand for comprehensive claims data from hospitals participating in the 340B Drug … Read more

Tariffs on South Korean autos, pharma, to rise to 25%

President Donald Trump announced Monday a new round of tariffs on goods imported from South Korea, increasing duties on autos, pharmaceuticals, and lumber from 15% to 25%. The action comes in response to a delay in the South Korean legislature’s approval of a trade deal initially reached with the United States last summer. Tariff Increase … Read more

How Johor-Singapore SEZ is delivering for businesses a year on

The Johor-Singapore Special Economic Zone: A New Frontier for AgTech and Beyond The recently launched Johor-Singapore Special Economic Zone (JS-SEZ) isn’t just another economic partnership; it’s a strategic response to evolving global challenges – and a potential blueprint for future cross-border economic collaboration. Driven by land scarcity in Singapore and the need for cost-effective production, … Read more

Novo Nordisk, Pfizer execs weigh in

The Shifting Sands of Pharma: Navigating Patent Cliffs, Deals, and a New Political Landscape The pharmaceutical industry entered 2026 with a cautious optimism, a sentiment echoing from the recent JPMorgan Healthcare Conference in San Francisco. While geopolitical uncertainties lingered in 2025, a potential turning point for the sector is on the horizon, fueled by falling … Read more

How To Improve Livestock Health To Meet Stock Show Standards, All Year Round

Keeping livestock healthy isn’t just a seasonal concern; it’s a year-round commitment, especially for those aiming for success in the show ring. But the future of livestock health management is rapidly evolving, moving beyond traditional practices towards a more proactive, data-driven, and technologically integrated approach. <h2>The Rise of Precision Livestock Farming</h2> <p>For decades, livestock health … Read more

Pharma & Biotech Moves: New Hires & Executive Changes | STAT News

The Revolving Door in Biotech: Why Executive Moves Signal Future Trends The pharmaceutical and biotechnology industries are known for a high degree of executive mobility. A seemingly simple “coming and going” announcement, like the recent hiring of Roger Waltzman as Chief Medical Officer at Biolojic Design (previously at Indaptus Therapeutics), is actually a powerful indicator … Read more

Supreme Court to Hear Case on Generic Drug ‘Skinny’ Labels

Supreme Court to Weigh ‘Skinny Labeling’ – What It Means for Generic Drugs and Your Wallet The Supreme Court’s decision to review the practice of “skinny labeling” by generic drug manufacturers is sending ripples through the pharmaceutical industry. This case isn’t just about legal technicalities; it has the potential to significantly impact the availability and … Read more

Lilly & Novo Nordisk Sued Over Weight Loss Drug Competition

Weight Loss Drugs: The Battle for Access Heats Up – What’s Next? The recent lawsuit filed by Strive Specialties against Eli Lilly and Novo Nordisk isn’t just about one compounding pharmacy; it’s a sign of a much larger battle brewing over the future of weight loss drug access. As demand for medications like Wegovy and … Read more

JPM24: Gilead’s Kite Pharma Faces FDA Decision on Myeloma Therapy

The Future of CAR-T Therapy: Beyond Multiple Myeloma and Gilead’s Next Moves The recent news regarding Gilead’s submission of anito-cel, a CAR-T therapy for multiple myeloma developed in partnership with Arcellx, isn’t just a single data point. It’s a flashing signal illuminating the evolving landscape of CAR-T (Chimeric Antigen Receptor T-cell) therapy and the broader … Read more